학술논문
Assessing the tolerability and toxicity of Levatinib plus Pembrolizumab for recurrent endometrial cancer: A real world experience (1110)
Document Type
Abstract
Author
Source
In Gynecologic Oncology September 2023 176 Supplement 1:S84-S84
Subject
Language
ISSN
0090-8258